Trastuzumab duocarmazine - Byondis
Alternative Names: (vic-)trastuzumab-duocarmazine; Anti-HER2 ADC - Byondis; Jivadco; SYD-985; Trastuzumab vc-seco-DUBA; Trastuzumab-SYD980Latest Information Update: 06 Dec 2023
At a glance
- Originator Synthon
- Developer Byondis; Yale University School of Medicine
- Class Antineoplastics; Bacterial toxins; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action Alkylating agents; Antibody-dependent cell cytotoxicity; DNA inhibitors; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preregistration HER2 positive breast cancer
- Phase II Endometrial cancer
- No development reported Gastric cancer; Gynaecological cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from the phase-III TULIP trial in Breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-20023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (IV, Infusion)
- 12 Sep 2023 Regulatory submission withdrawn for HER2-positive-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union (IV)